Moderately to Severely Active Crohn's Disease

DrugDrug NameDrug Description
DB00051AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
DrugDrug NameTargetType
DB00051AdalimumabTumor necrosis factortarget
DrugDrug NamePhaseStatusCount
DB08904Certolizumab pegol3Completed1